NICE’s ICER threshold change is about what kind of launch market the UK wants to be

Last time I wrote, I made a point that is still being debated. The UK isn’t rejecting medicines. It’s losing them before NICE even sees them. Not because the science isn’t there or the evidence isn’t strong enough, but because the commercial risk, particularly MFN, is starting to shape behaviour upstream. You can see it in hesitancy, in pulled submissions, in appraisals that never quite make it to a decision. So, when NICE raises the ICER threshold, I don’t really care whether it’s framed as a methodological improvement. The real question is whether it changes that behaviour. Because widening the door at NICE only matters if companies are still willing to walk up to it in the first place.

I think a lot of people are still reading NICE’s threshold change too narrowly. When NICE announced on 2 April 2026 that its committees would move immediately from the long-standing £20,000–£30,000 per QALY range to £25,000–£35,000, the easy interpretation was that this was a technical tweak to the methods manual. The more interesting interpretation is that it is really a signal about access, pricing and the UK’s place in global launch strategy and its efforts to mitigate America’s MFN policy.

What makes the move important is that the numbers are not trivial, even if they are not transformational on their own. NICE says it already recommends 91% of the medicines it evaluates, roughly 70 a year, and that the higher threshold should allow 3 to 5 additional medicines or indications to be approved each year. If you project that across a five-year period, you get something like 15 to 25 extra positive TA outcomes. That is not the same thing as 15 to 25 blockbuster launches, and it probably does not map neatly onto 15 to 25 separate appraisal numbers, but it is still a meaningful shift in the marginal cases that used to sit just outside the old range.

Just as importantly, this is not NICE throwing open the gates. The updated manual still says that below £25,000 per QALY, the recommendation is normally driven by the cost-effectiveness estimate; between £25,000 and £35,000, committees must make explicit reference to uncertainty, uncaptured benefits and health inequalities; and above £35,000, they need an increasingly stronger case. So, the real change is not that higher-priced products suddenly get an automatic yes. It is that borderline products now have a wider and more workable zone in which to argue their value.

There is another nuance that matters. NICE has been clear that the change is not retrospective: it will not routinely go back and reopen old negative decisions. The new range applies to appraisals that are new or already underway, and it applies to the standard technology appraisal programme rather than the highly specialised technologies route. In practical terms, that means the story here is less about rewriting the last five years and more about changing the economics of the next five.

That is where the looming MFN threat comes in. If you look at the threshold change in isolation, it only partially mitigates Most-Favoured-Nation pricing risk. It does not remove international reference pricing, and it does not make the UK invisible to global pricing teams. What it does do is reduce the pressure to accept a very low UK clearing price simply to get through NICE, which makes the UK less commercially toxic as an early launch market. To me, that makes the threshold increase an indirect MFN mitigation rather than a full fix.

The broader UK-US arrangement makes that logic much clearer. In the policy paper published on 2 April 2026, the UK commits to increasing the NHS net price paid for prospective new medicines by 25% from April 2026, using the higher NICE QALY range and the introduction of EQ-5D-5L, while also saying that the uplift should not be materially eroded by additional access barriers, tighter utilisation controls or higher rebates. The same arrangement says VPAG repayments will fall to 15%, and that the total effective portfolio-wide rebate for new medicines will not exceed 16% while the current VPAG remains in force. So, this is not just about moving a threshold on paper; it is about protecting more of the realised net price in practice.

The most direct MFN mitigation, though, is not the NICE change itself. The US states that where the UK price for a new medicine is the lowest in the reference basket, the Medicaid MFN price will not anchor on that lowest UK price. It also says future GLOBE and GUARD models are expected to contain provisions to mitigate launch risk in lower-priced countries, and both governments say they expect companies not to delay innovative launches in the UK. Taken together, that looks much bigger than a health economics adjustment. It looks like a coordinated attempt to make the UK commercially usable again without pretending global price referencing has disappeared.

My thoughts are that this is neither a revolution nor a cosmetic tweak. It is a deliberate attempt to widen the NICE decision window, improve realised UK net price, and soften some of the launch-order penalties that have made the UK a difficult first-wave market. The old trade-off is still there, but it looks much less rigid than it did before this change. The real question now is whether global launch teams believe the signal strongly enough to change behaviour.

Do you think this genuinely moves the UK up the launch list, or is it still a better-packaged version of the old compromise?